Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.
Pascuale CA, Varese A, Ojeda DS, Pasinovich ME, Lopez L, Rossi AH, Rodriguez PE, Miglietta EA; Laboratorio SeVa Group; Mazzitelli I, Di Diego Garcia F, Sanchez L, Rouco SO, Gonzalez Lopez Ledesma MM, Zurano JP, Mazzitelli B, Scruzzi G, Barbero P, Cardozo D, Gallego S, Borda M, Diaz M; Ministerio de Salud de la Provincia de Córdoba Group; UNC-Fac. Cs. Médicas-InViV Group; Ridao F, Rosales AB; Ministerio de Salud de la Provincia de La Rioja Group; Bhon J, Talia JM, Diangelo ME, Lacaze MA; Ministerio de Salud de la Provincia de San Luis Group; Aime B, Gutierrez SI, Ercole R, Toro R, Tau L, Delaplace L, Compagnucci MF; Universidad Nacional de La Plata Group; Sartori C, Desimone I, Echegoyen C, Velazquez P, Testa C; Ministerio de Salud de la Provincia de Buenos Aires Group; Hozbor D, Docena G, Laino CH, Kreplak N, Pifano M, Barbas G, Rearte A, Vizzotti C, Castelli JM, Geffner J, Gamarnik AV.
Pascuale CA, et al.
Cell Rep Med. 2022 Aug 16;3(8):100706. doi: 10.1016/j.xcrm.2022.100706. Epub 2022 Aug 3.
Cell Rep Med. 2022.
PMID: 35926505
Free PMC article.